文献速递头颈与中枢神经肿瘤

替莫唑胺时代胶质母细胞瘤基于分子的递归分割分析模型:基于NRG Oncology RTOG 0525的相关性分析

Molecular-Based Recursive Partitioning Analysis Model for Glioblastoma in the Temozolomide Era: A Correlative Analysis Based on NRG Oncology RTOG 0525.
PubMed 文献 · JAMA Oncol · 2017-01-01

本研究基于NRG Oncology RTOG 0525试验的452例胶质母细胞瘤标本,采用定量分子显微镜方法分析蛋白生物标志物,并将显著标志物与临床变量整合,建立新的递归分割分析模型(NRG-GBM-RPA)。新模型由MGMT蛋白、c-Met蛋白和年龄组成,在NRG Oncology RTOG 0525中较现有RTOG RPA模型和MGMT启动子甲基化显示出更好的总生存预后分层,并在独立数据集(n=176)中得到验证。

要点

  • MGMT蛋白水平高与MGMT启动子甲基化降低显著相关,且MGMT蛋白对总生存的预后价值大于启动子甲基化。
  • 新模型NRG-GBM-RPA由MGMT蛋白、c-Met蛋白和年龄组成,较现有RTOG RPA模型和MGMT启动子甲基化显示出更好的生存分层。
  • 新模型的预后意义在独立数据集(n=176)中得到验证。

核心结论

  • 新NRG-GBM-RPA模型在接受放疗和替莫唑胺治疗的胶质母细胞瘤患者中,较现有RTOG RPA模型和MGMT启动子甲基化分别改善了结局分层,并在独立数据集中得到生物学验证。
  • 修订后的RPA有可能有助于改善接受放疗和替莫唑胺治疗的胶质母细胞瘤患者预后分组的准确评估,并影响临床决策。

研究设计与样本

  • 对NRG Oncology RTOG 0525试验的452例标本进行分析,采用基于定量分子显微镜的方法检测代表胶质母细胞瘤关键通路的蛋白生物标志物,并用半定量免疫组织化学验证。
  • 通过单标志物和多标志物Cox回归分析检验每种蛋白的预后意义,将单标志物分析中显著的蛋白标志物与现有RTOG RPA相同的临床变量(年龄、Karnofsky体能状态、切除范围、神经功能)整合建立新RPA模型(NRG-GBM-RPA)。
  • 新模型在独立数据集(n=176)中使用传统免疫组织化学进行确认。
  • 用于建立新NRG-GBM-RPA模型的166例患者中,97例(58.4%)为男性,平均年龄55.7岁(标准差12.0)。

主要发现

  • 在452例标本中,单标志物多变量分析显示以下蛋白水平与总生存显著相关:MGMT(风险比[HR] 1.81;95%CI 1.37-2.39;P<.001)、survivin(HR 1.36;95%CI 1.04-1.76;P=.02)、c-Met(HR 1.53;95%CI 1.06-2.23;P=.02)、pmTOR(HR 0.76;95%CI 0.60-0.97;P=.03)和Ki-67(HR 1.40;95%CI 1.10-1.78;P=.007)。
  • 较高的MGMT蛋白水平与MGMT启动子甲基化降低显著相关,反之亦然(甲基化组1425.1 vs 未甲基化组1828.0;P<.001)。
  • MGMT蛋白表达(HR 1.84;95%CI 1.38-2.43;P<.001)对总生存的预后价值大于MGMT启动子甲基化(HR 1.77;95%CI 1.28-2.44;P<.001)。
  • 由MGMT蛋白、c-Met蛋白和年龄组成的修订NRG-GBM-RPA在NRG Oncology RTOG 0525中较现有临床RPA模型和MGMT启动子甲基化显示出更大的总生存预后类别分离。
  • NRG-GBM-RPA的预后意义随后在独立数据集(n=176)中得到确认。

关键数值与推荐

  • 现有RTOG RPA的临床变量包括年龄、Karnofsky体能状态、切除范围和神经功能。
  • 单标志物分析中显著的蛋白标志物为MGMT、survivin、c-Met、pmTOR和Ki-67。
  • 新NRG-GBM-RPA模型由MGMT蛋白、c-Met蛋白和年龄组成。

临床怎么用

  • 新NRG-GBM-RPA模型有可能有助于改善接受放疗和替莫唑胺治疗的胶质母细胞瘤患者预后分组的准确评估,并影响临床决策。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: There is a need for a more refined, molecularly based classification model for glioblastoma (GBM) in the temozolomide era. OBJECTIVE: To refine the existing clinically based recursive partitioning analysis (RPA) model by incorporating molecular variables. DESIGN, SETTING, AND PARTICIPANTS: NRG Oncology RTOG 0525 specimens (n = 452) were analyzed for protein biomarkers representing key pathways in GBM by a quantitative molecular microscopy-based approach with semiquantitative immunohistochemical validation. Prognostic significance of each protein was examined by single-marker and multimarker Cox regression analyses. To reclassify the prognostic risk groups, significant protein biomarkers on single-marker analysis were incorporated into an RPA model consisting of the same clinical variables (age, Karnofsky Performance Status, extent of resection, and neurologic function) as the existing RTOG RPA. The new RPA model (NRG-GBM-RPA) was confirmed using traditional immunohistochemistry in an independent data set (n = 176). MAIN OUTCOMES AND MEASURES: Overall survival (OS). RESULTS: In 452 specimens, MGMT (hazard ratio [HR], 1.81; 95% CI, 1.37-2.39; P < .001), survivin (HR, 1.36; 95% CI, 1.04-1.76; P = .02), c-Met (HR, 1.53; 95% CI, 1.06-2.23; P = .02), pmTOR (HR, 0.76; 95% CI, 0.60-0.97; P = .03), and Ki-67 (HR, 1.40; 95% CI, 1.10-1.78; P = .007) protein levels were found to be significant on single-marker multivariate analysis of OS. To refine the existing RPA, significant protein biomarkers together with clinical variables (age, Karnofsky Performance Status, extent of resection, and neurological function) were incorporated into a new model. Of 166 patients used for the new NRG-GBM-RPA model, 97 (58.4%) were male (mean [SD] age, 55.7 [12.0] years). Higher MGMT protein level was significantly associated with decreased MGMT promoter methylation and vice versa (1425.1 for methylated vs 1828.0 for unmethylated; P < .001). Furthermore, MGMT protein expression (HR, 1.84; 95% CI, 1.38-2.43; P < .001) had greater prognostic value for OS compared with MGMT promoter methylation (HR, 1.77; 95% CI, 1.28-2.44; P < .001). The refined NRG-GBM-RPA consisting of MGMT protein, c-Met protein, and age revealed greater separation of OS prognostic classes compared with the existing clinically based RPA model and MGMT promoter methylation in NRG Oncology RTOG 0525. The prognostic significance of the NRG-GBM-RPA was subsequently confirmed in an independent data set (n = 176). CONCLUSIONS AND RELEVANCE: This new NRG-GBM-RPA model improves outcome stratification over both the current RTOG RPA model and MGMT promoter methylation, respectively, for patients with GBM treated with radiation and temozolomide and was biologically validated in an independent data set. The revised RPA has the potential to contribute to improving the accurate assessment of prognostic groups in patients with GBM treated with radiation and temozolomide and to influence clinical decision making. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00304031.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Bell EH, Pugh SL, McElroy JP, et al. Molecular-Based Recursive Partitioning Analysis Model for Glioblastoma in the Temozolomide Era: A Correlative Analysis Based on NRG Oncology RTOG 0525. JAMA Oncol. 2017. PMID: 28097324. doi:10.1001/jamaoncol.2016.6020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。